1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
2
|
Baldewijns MM, van Vlodrop IJ, Schouten
LJ, Soetekouw PM, de Bruïne AP and van Engeland M: Genetics and
epigenetics of renal cell cancer. Biochim Biophys Acta.
1785:133–155. 2008.PubMed/NCBI
|
3
|
Drucker BJ: Renal cell carcinoma: Current
status and future prospects. Cancer Treat Rev. 31:536–545. 2005.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Huang Y, Dai Y, Yang J, Chen T, Yin Y,
Tang M, Hu C and Zhang L: Microarray analysis of microRNA
expression in renal clear cell carcinoma. Eur J Surg Oncol.
35:1119–1123. 2009. View Article : Google Scholar : PubMed/NCBI
|
5
|
Shagisultanova E, Gaponova AV, Gabbasov R,
Nicolas E and Golemis EA: Preclinical and clinical studies of the
NEDD9 scaffold protein in cancer and other diseases. Gene.
567:1–11. 2015. View Article : Google Scholar : PubMed/NCBI
|
6
|
Kim M, Gans JD, Nogueira C, Wang A, Paik
JH, Feng B, Brennan C, Hahn WC, Cordon-Cardo C, Wagner SN, et al:
Comparative oncogenomics identifies NEDD9 as a melanoma metastasis
gene. Cell. 125:1269–1281. 2006. View Article : Google Scholar : PubMed/NCBI
|
7
|
Natarajan M, Stewart JE, Golemis EA,
Pugacheva EN, Alexandropoulos K, Cox BD, Wang W, Grammer JR and
Gladson CL: HEF1 is a necessary and specific downstream effector of
FAK that promotes the migration of glioblastoma cells. Oncogene.
25:1721–1732. 2006. View Article : Google Scholar : PubMed/NCBI
|
8
|
Tornillo G, Defilippi P and Cabodi S: Cas
proteins: Dodgy scaffolding in breast cancer. Breast Cancer Res.
16:4432014. View Article : Google Scholar : PubMed/NCBI
|
9
|
Loskutov YV, Kozyulina PY, Kozyreva VK,
Ice RJ, Jones BC, Roston TJ, Smolkin MB, Ivanov AV, Wysolmerski RB
and Pugacheva EN: NEDD9/Arf6-dependent endocytic trafficking of
matrix metalloproteinase 14: A novel mechanism for blocking
mesenchymal cell invasion and metastasis of breast cancer.
Oncogene. 34:3662–3675. 2015. View Article : Google Scholar : PubMed/NCBI
|
10
|
Kondo S, Iwata S, Yamada T, Inoue Y,
Ichihara H, Kichikawa Y, Katayose T, Souta-Kuribara A, Yamazaki H,
Hosono O, et al: Impact of the integrin signaling adaptor protein
NEDD9 on prognosis and metastatic behavior of human lung cancer.
Clin Cancer Res. 18:6326–6338. 2012. View Article : Google Scholar : PubMed/NCBI
|
11
|
Wang J, Yang WJ, Sun C, Luan Y, Cheng GH,
Li KL and Kong F: siRNA suppression of NEDD9 inhibits proliferation
and enhances apoptosis in renal cell carcinoma. Oncol Res.
22:219–224. 2014. View Article : Google Scholar : PubMed/NCBI
|
12
|
Han T, Yi XP, Liu B, Ke MJ and Li YX:
MicroRNA-145 suppresses cell proliferation, invasion and migration
in pancreatic cancer cells by targeting NEDD9. Mol Med Rep.
11:4115–4120. 2015. View Article : Google Scholar : PubMed/NCBI
|
13
|
Izumchenko E, Singh MK, Plotnikova OV,
Tikhmyanova N, Little JL, Serebriiskii IG, Seo S, Kurokawa M,
Egleston BL, Klein-Szanto A, et al: NEDD9 promotes oncogenic
signaling in mammary tumor development. Cancer Res. 69:7198–7206.
2009. View Article : Google Scholar : PubMed/NCBI
|
14
|
Eble J, Sauter G, Epstein J and Sesterhenn
IE: World health organization classification of tumors pathology
and genetics of the urinary systemandmale genital organs. LARC
Press; Lyon: pp. 12–14. 2004
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-timequantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Tikhmyanova N, Tulin AV, Roegiers F and
Golemis EA: Dcas supports cell polarization and cell-cell adhesion
complexes in development. PLoS One. 5:e123692010. View Article : Google Scholar : PubMed/NCBI
|
17
|
Nikonova AS, Gaponova AV, Kudinov AE and
Golemis EA: CAS proteins in health and disease: An update. IUBMB
Life. 66:387–395. 2014. View
Article : Google Scholar : PubMed/NCBI
|
18
|
O'Neill GM, Seo S, Serebriiskii IG, Lessin
SR and Golemis EA: A new central scaffold for metastasis: Parsing
HEF1/Cas-L/NEDD9. Cancer Res. 67:8975–8979. 2007. View Article : Google Scholar : PubMed/NCBI
|
19
|
Xue YZ, Sheng YY, Liu ZL, Wei ZQ, Cao HY,
Wu YM, Lu YF, Yu LH, Li JP and Li ZS: Expression of NEDD9 in
pancreatic ductal adenocarcinoma and its clinical significance.
Tumour Biol. 34:895–899. 2013. View Article : Google Scholar : PubMed/NCBI
|
20
|
Li P, Zhou H, Zhu X, Ma G, Liu C, Lin B
and Mao W: High expression of NEDD9 predicts adverse outcomes of
colorectal cancer patients. Int J Clin Exp Pathol. 7:2565–2570.
2014.PubMed/NCBI
|
21
|
Shi R, Wang L, Wang T, Xu J, Wang F and Xu
M: NEDD9 overexpression correlates with the progression and
prognosis in gastric carcinoma. Med Oncol. 31:8522014. View Article : Google Scholar : PubMed/NCBI
|
22
|
Wan L, Pantel K and Kang Y: Tumor
metastasis: Moving new biological insights into the clinic. Nat
Med. 19:1450–1464. 2013. View
Article : Google Scholar : PubMed/NCBI
|
23
|
Zeng G, Gao L and Yu RK: Reduced cell
migration, tumor growth and experimental metastasis of rat F-11
cells whose expression of GD3-synthase is suppressed. Int J Cancer.
88:53–57. 2000. View Article : Google Scholar : PubMed/NCBI
|
24
|
Shin KD, Lee MY, Shin DS, Lee S, Son KH,
Koh S, Paik YK, Kwon BM and Han DC: Blocking tumor cell migration
and invasion with biphenyl isoxazole derivative KRIBB3, a synthetic
molecule that inhibits Hsp27 phosphorylation. J Biol Chem.
280:41439–41448. 2005. View Article : Google Scholar : PubMed/NCBI
|
25
|
Feng J, Zhao J, Xie H, Yin Y, Luo G, Zhang
J, Feng Y and Li Z: Involvement of NEDD9 in the invasion and
migration of gastric cancer. Tumour Biol. 36:3621–3628. 2015.
View Article : Google Scholar : PubMed/NCBI
|